Can a spinal fluid test diagnose Parkinson’s? Researchers have identified DOPA decarboxylase as a key biomarker that separates Parkinson’s and Lewy body dementia from other forms of cognitive decline.
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy –– ARV-102 ...
INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys ® Total-Tau CSF assays (tTau) have received U.S. Food and Drug ...
Cerebrospinal fluid (CSF) and other biomarkers differ for individuals with Alzheimer disease and cognitively normal controls, with the estimated times of divergence varying from 18 to six years before ...
At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, Eli Lilly and Company presented new data evaluating the ...
OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results